Matthew Philip Goetz, MD

  • 8099 Citations
  • 41 Scopus h-Index
20022021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Matthew Philip Goetz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Tamoxifen Medicine & Life Sciences
Cytochrome P-450 CYP2D6 Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Hormonal Antineoplastic Agents Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2005 2021

Breast Neoplasms
Research Personnel
Research
Biostatistics
Translational Medical Research
Pharmacogenetics
Tamoxifen
Biotransformation
Cytochrome P-450 CYP2D6
Breast Neoplasms

Research Output 2002 2019

5 Citations (Scopus)

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

Veeraraghavan, J., De Angelis, C., Mao, R., Wang, T., Herrera, S., Pavlick, A. C., Contreras, A., Nuciforo, P., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Chang, J. C., Wolff, A. C., Krop, I. E., Fuqua, S. A. W., Prat, A., Hilsenbeck, S. G., Weigelt, B., Reis-Filho, J. S. & 4 others, Gutierrez, C., Osborne, C. K., Rimawi, M. F. & Schiff, R., Jun 1 2019, In : Annals of Oncology. 30, 6, p. 927-933 7 p., mdz076.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Biomarkers
Breast Neoplasms
Drug Therapy
Fluorescence In Situ Hybridization

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2

Dudenkov, T. M., Liu, D., Cairns, J., Devarajan, S., Zhuang, Y., Ingle, J. N., Buzdar, A. U., Robson, M. E., Kubo, M., Batzler, A., Barman, P., Jenkins, G. D., Carlson, E. E., Goetz, M. P., Northfelt, D. W., Moreno Aspitia, A., Desta, Z., Reid, J. M., Kalari, K. R., Wang, L. M. & 1 others, Weinshilboum, R. M., Jan 1 2019, In : Clinical pharmacology and therapeutics.

Research output: Contribution to journalArticle

Open Access
Aromatase Inhibitors
Genome-Wide Association Study
Single Nucleotide Polymorphism
Pharmaceutical Preparations
Breast Neoplasms
16 Citations (Scopus)

Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Farrar, W. B., Giordano, S. H., Goldstein, L. J., Isakoff, S. J., Lyons, J., Kelly Marcom, P., Mayer, I. A., Moran, M. S., Mortimer, J., O’Regan, R. M. & 13 others, Patel, S. A., Pierce, L. J., Reed, E. C., Rugo, H. S., Sitapati, A., Smith, K. L., Smith, M. L., Soliman, H., Telli, M. L., Ward, J. H., Young, J. S., Shead, D. A. & Kumar, R., Feb 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 2, p. 118-126 9 p.

Research output: Contribution to journalArticle

Open Access
Adjuvant Chemotherapy
Hormones
Guidelines
Breast Neoplasms
Therapeutics
26 Citations (Scopus)

Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Keane, M. M. & 10 others, Gomez Moreno, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D. L., Kaklamani, V. G., Berenberg, J. L., Abrams, J. & Sledge, G. W., Jun 20 2019, In : New England Journal of Medicine. 380, 25, p. 2395-2405 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Recurrence
Therapeutics
Drug Therapy
Confidence Intervals
1 Citation (Scopus)

Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., Hayes, D. F. & 9 others, Dees, E. C., Geyer, C. E., Olson, J. A., Wood, W. C., Lively, T., Paik, S., Ellis, M. J., Abrams, J. & Sledge, G. W., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journalArticle

Open Access
Adjuvant Chemotherapy
Randomized Controlled Trials
Breast Neoplasms
Recurrence
Genes